Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Newly Passed Chinese Patent Law Allows Government To Issue Compulsory Licenses On Patented Drugs

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - The Third Amendment of China's new Patent Laws passed by the 6th Session of the 11th Standing Committee of the National People's Congress on Dec. 27, means that the government can issue compulsory licenses on patented drugs in China, according to the new amendment

You may also be interested in...



China To Implement New Regulations For Patent Law; Companies Should Set Up Inventor Reward Policy To Prepare For Changes

SHANGHAI - China's State Council recently approved new implementation regulations for the country's Patent law, which clarifies procedural issues in line with new changes to the patent law that took effect last year

China To Implement New Regulations For Patent Law; Companies Should Set Up Inventor Reward Policy To Prepare For Changes

SHANGHAI - China's State Council recently approved new implementation regulations for the country's Patent law, which clarifies procedural issues in line with new changes to the patent law that took effect last year

Intellectual Property Protection In China Improving In Incremental Stages - BioBusiness 2009 Conference

TAIPEI - China, generally thought to be a black hole for intellectual property, may be less dangerous for research-intensive pharmaceutical companies than is generally thought

Related Content

UsernamePublicRestriction

Register

LL1125120

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel